Information Provided By:
Fly News Breaks for March 14, 2018
AMAG
Mar 14, 2018 | 06:39 EDT
B. Riley FBR analyst David Buck raised his price target for Amag Pharmaceuticals to $23 citing to reflect the high end of guidance adjusted EBITDA estimates and a lack of early-February generic competition to Makena. The analyst, however, keeps a Neutral rating on the shares. He believes Amag's ability to grow beyond 2019 "still depends upon maintaining some tail for Makena."
News For AMAG From the Last 2 Days
There are no results for your query AMAG
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.